

Neurology Medical Group of Diablo Valley
108 La Casa Via
Suite 105
Walnut Creek, CA 94598
Phone: 925-939-2272- Research Office
Fax: 925-407-0505- Research Office

Janet F. Hornstein Lin , MD

Certifications

American Board of Psychiatry and Neurology - Neurology (Diplomate)	1983
National Board of Medical Examiners (Diplomate)	1978

Licensure

MD - G41717, California

Academic Degrees

MD - New Jersey College of Medicine & Dentistry, Newark, NJ	1977
BA - Literature, Antioch College, Yellow Springs, OH	1972

Residencies and Internships

Chief Resident - Neurology, New Jersey College of Medicine & Dentistry, Newark, NJ	July 1980 – June 1981
Resident - Neurology, New Jersey College of Medicine & Dentistry, Newark, NJ	July 1978 – June 1980
Internship – Internal Medicine, New Jersey College of Medicine & Dentistry, Newark, NJ	July 1977 – June 1978

Professional Societies

Alameda-Contra Costa Medical Association	1981 – present
California Medical Association	1981 – present
American Academy of Neurology	1979 – present
San Francisco Neurologic Association	1981 – 1990

Experience

Private Practice of Neurology - Neurology Medical Group of Diablo Valley, Walnut Creek, CA	1981 – present
--	----------------

Appointments

Chairperson & Member - Bylaws Committee, John Muir Medical Center, Walnut Creek, CA	1992 – 1999
Chairperson & Member - Ethics Committee, John Muir Medical Center, Walnut Creek, CA	1986 - present
Part-time Lecturer - School of Optometry, University of California Berkeley, Berkeley, CA	1996

Co-Director - Neurosciences Intensive Care Unit, John Muir Medical Center, Walnut Creek, CA	1992 - 1994
Member - ICU Committee, John Muir Medical Center, Walnut Creek, CA	1991 - 1994
Neuro Section Chair - John Muir Medical Center, Walnut Creek, CA	1990 - 1992
Member - Neuro ICU Committee, John Muir Medical Center, Walnut Creek, CA	1990 - 1991
Medical Consultant - Tri-Valley Rehabilitation Program, Danville, CA	1983 - 1990
Co-Chairperson - Annual Joint Ethnicity Seminar, John Muir Medical Center & Mt. Diablo Medical Center	1987 - 1988

Current Hospital Affiliations

John Muir Medical Center - Walnut Creek, CA
Mt. Diablo Medical Center - Concord, CA

Presentations & Publications

Lin J FH, "Introduction to Fragile X Syndrome for Parents." Dev Brain Dysfunction, 8: 359-362, 1995.

Research Activities

PRINCIPAL INVESTIGATOR

A Randomized, Rater-blinded, Multicenter, Parallel-group Study Comparing the Efficacy and Safety of Betaseron® 250µg Subcutaneously Every Other Day with Avonex® 30µg Intramuscularly Once per Week in Relapsing-remitting Multiple Sclerosis Patients Previously Treated with Avonex® (ABOVE)	2003 – 2005
Medical Index for Neuromuscular Data (MIND) Registry	2002 – 2004
Randomized, Double-Blind, Parallel Group Study of the Safety and Efficacy of Latranal Compared to Doxepin Cream and Placebo in Patients with Chronic Low Back Pain	2001
"Topamax Monotherapy Comparison Trial to Standard Monotherapy in the Treatment of Newly Diagnosed Epilepsy."	1998 – 2000

SUBINVESTIGATOR

A double-blind, active and placebo-controlled study of Aggrenox® vs. Clopidogrel + aspirin, with and without Micardis® (PRoFESS)	2003 – present
A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess The Efficacy and Safety of Intravenous NXY-059 In Acute Ischemic Stroke (SAINT)	2003 – present
A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled, Fixed Dose Response Study Comparing the Efficacy and Safety of Sumanriole versus Placebo in Patients with Early Parkinson's Disease	2003 - 2005

E2020-A001-319 A 24-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy, Safety and Tolerability of Donepezil Hydrochloride (E2020) in Patients with Dementia Associated with Cerebrovascular Disease	2003– 2004
A Multicenter, Prospective and Retrospective, Long-Term Observational Study of AVONEX ® and Rebif® to Determine the Efficacy, Tolerability, and Safety in Subjects with Relapsing Multiple Sclerosis (MS) (PROOF)	2003 – 2004
Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)	2003 – 2005
Phase I, A Single Rising Dose Study of FK506 Lipid Complex (LCG) in Patients With Recent Ischemic Stroke	2002 – 2004
A Multi-Center, open-label, randomized, 4-way crossover trial of the safety and Efficacy of Tizanidine Hydrochloride Capsules versus Zanaflex® (Tizanidine Hydrochloride) Tablets taken under fed and fasted conditions in patients with Moderate to severe Spasticity	2002
A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Comparing the Efficacy, Safety, and Tolerability of Sumanitrole versus Placebo or Ropinrole in Patients with Early Parkinson's Disease	2002 – 2003
Open-Label, Long-Term, Flexible Dose Study of Safety, Tolerability and Therapeutic Response in Patients with Parkinson's Disease: PNU-9566E	2002 – 2004
Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischemic Attack or Ischemic Stroke: A Randomized, Double-Blind Study, With 18 Months Follow-up. (MATCH)	2001 – 2004
A Randomized, Placebo-Controlled, Three Treatment Arm Study to Determine the Safety and Efficacy of Argatroban Injection in Patients with Acute Ischemic Stroke	2001 – 2002
Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Effects of YM872 on Lesion Volume as Measured by Diffusion, Perfusion and FLAIR Magnetic Resonance Imaging in Patients with Acute Ischemic Stroke. (ARTIST MRI)	2001 - 2003
Multicenter, Stratified, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Neurologic Function and Disability in Patients with Acute Ischemic Stroke Given Tissue Plasminogen Activator Plus YM872 or Tissue Plasminogen Activator Plus Placebo. (ARTIST +)	2001 - 2003
Phase III Multicenter, Double-Blind, Parallel-Group Placebo Controlled Study of the Effect of Riluzole 50 mg BID or 100 mg BID on the Progression of Parkinson's Disease in Patients Treated with L-Dopa or Dopamine Agonist	2001
Phase II, 12 Week, Randomized, Double-Blind, Placebo Controlled, Multicenter Study Evaluating the Safety and Efficacy of Three Fixed Doses of Oral CP-457,920 (30 mg QD, 60 mg BID and 120 mg BID) and Donepezil in Outpatients with Alzheimer's Disease	2000 – 2002
Efficacy and Safety Study of the Oral Direct Thrombin Inhibitor H 376/95 Compared with Dose-Adjusted Warfarin (Coumadin©) in the Prevention of Stroke and Systemic Embolic Events in Patients with Atrial Fibrillation (SPORTIF V)	2000 – 2003

Acute Ischemic Stroke Protocol 161-106, Phase II	2000
Lamictal® in Combination with Newer and Older Antiepileptic Drugs and as Monotherapy: A Practical Clinical Assessment of Tolerability and Clinical Effectiveness (The TARGET Study: <u>T</u> rial to <u>A</u> ssess and <u>R</u> efine <u>G</u> lobal <u>E</u> pilepsy <u>T</u> reatment)"	1999 – 2000
"Blockade of the GP IIB/IIIa Receptor to Avoid Vascular Occlusion (BRAVO), Phase III."	1999 – 2001
"A Phase III, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Hu23F2G (LeukArrest™) in Patients with Acute Ischemic Stroke."	1999 – 2000
"The Safety and Efficacy of MK-0966 in Slowing the Progression of the Symptoms of Alzheimer's Disease."	1999 – 2000
Pregabalin BID, Open-Label, Add-On Trial: "An Open-Label, Multicenter, Follow-On Study to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures."	1998 – 2005
Pregabalin BID Add-On Trial: "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study in Patients with Partial Seizures."	1998 – 1999
"A 4-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Three Dose Levels of Prosaptide When Administered Daily for 28 Days by Subcutaneous Injection on Diabetic Painful Neuropathy in Patients with Type 1 or Type 2 Diabetes Mellitus."	1998 – 1999
The Acute Stroke Study in Ischemic Stroke (Class-I): "A Double-Blind, Parallel-Group, Multinational, Multicenter Study of the Efficacy and Safety of IV Compound Compared to Placebo in Patients with Acute Ischemic Stroke."	1997 - 2000
The Acute Stroke Study in Acute Intracerebral Hemorrhage (Class-H): A Double-Blind, Parallel-Group, Multinational, Multicenter Study of Safety of IV Compound Compared to Placebo in Patients with Acute Intracerebral Hemorrhage."	1997 - 1999
The Acute Stroke Study in t-PA Treated Ischemic Stroke (Class-T): "A Double-Blind, Parallel-Group, Multinational, Multicenter Study of the Safety of IV Compound Compared to Placebo in Patients Treated with t-PA (Tissue Plasminogen Activator) for Acute Ischemic Stroke."	1997 - 1999
An Open-Label Study to Evaluate the Safety and Efficacy of 1.5 mg b.i.d. (3 mg/day) through 6 mg b.i.d.(12 mg/day) of Exelon in Patients with Mild to Severe Probable Alzheimer's Disease in the Community Setting."	1997 – 1999
"Enlimomab Acute Stroke Study, Phase III."	1995 – 1996